Onco Actu du 4 juin 2020

	1. BIOLOGIE
‘Terminator’ protein halts cancer-causing cellular processes [Cornell] The paper “TiPARP Forms Nuclear Condensates to Degrade HIF-1α and Suppress Tumorigenesis,” published in PNAS, establishes TiPARP as a turning-off mechanism for several important transcription factors.
	2.9 ETIOLOGIE - TABAC
Cancer risk for non-daily smokers 4 times higher than non-smokers [UPI] For their study, researchers from the National Cancer Institute reviewed data on tobacco use and health outcomes for more than 505,000 U.S. adults over a 20-year period. Daily smokers in the study smoked roughly 20 cigarettes a day, while non-daily smokers smoked roughly 40 per month, the authors said.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
How a Delay in Colonoscopy Screening May Affect Cancer Risk [NY Times] The analysis, in Annals of Internal Medicine, included 165,887 men and women aged 50 to 66 who had a single negative colonoscopy.
	5. TRAITEMENTS
New method of manufacturing targeted drugs could lead to better cancer treatments [USC] The current way to make a highly targeted type of drug called “antibody-drug conjugates” is lengthy and inefficient. Scientists at the USC School of Pharmacy have engineered something better.
	5.2.1 PHARMA - PARTENARIATS
AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics [AstraZeneca] This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause resistance to medicines.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma [BeiGene] First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
EMA Recommends Extension of Indications for Olaparib [ESMO] New indication concerns maintenance treatment of metastatic adenocarcinoma of the pancreas with germline BRCA1/2-mutations.
	5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)
Durable Remission, Rare Adverse Effects With Anti-CD19 CAR-T Therapy in CLL, Lymphoma [Oncology Times] "These long-term remissions raise the possibility, but do not prove that CAR T cells could be curative for some B-cell lymphomas, including diffuse large B-cell lymphoma, low-grade lymphomas, and CLL," first author Kathryn Cappell, MD, PhD, told Oncology Times.
	6.1 OBSERVATION
Study Puts Price Tag on Lost Earnings from Racial Disparities in Cancer Mortality [ACS] $3.2 Billion in lost earnings would be avoided in 2015 alone had mortality and earning been equal between blacks and whites.